Peptide Therapy Cost: National Breakdown (2026)

Peptide therapy has no single price, and for most of the category it has no published price at all. Brand GLP-1 drugs are the exception: Novo Nordisk publishes $1,349.02 per package for Wegovy and $1,027.51 per month for Ozempic, and a manufacturer self-pay program at $349/month. Compounded research peptides like BPC-157 are quoted per pharmacy and per program, with no list price anyone publishes — so this guide covers what drives the number and how to compare two quotes, rather than a range we cannot source. Consultation and lab fees are extra and are rarely published either. Insurance rarely covers non-FDA-approved peptides.

Peptide therapy cost at a glance

• Compounded "research" peptides (BPC-157, TB-500, CJC-1295/ipamorelin): no published price. Each pharmacy or telehealth program quotes its own rate; we publish no range, because the ranges we used to carry were advertised figures we never verified
• GLP-1 weight-loss drugs, brand list price: $1,349.02 per package for Wegovy; $1,027.51 per month for Ozempic (NovoCare, retrieved September 2026)
• GLP-1 drugs, manufacturer self-pay: $349/month for Wegovy at any dose, $399/month for the HD 7.2 mg pen (NovoCare). Lilly publishes a Zepbound KwikPen self-pay ladder per dose — a regular $299/month at 2.5 mg rising to $699/month at the top three doses, with a $449/month purchase offer at 7.5 mg and above — and our price-per-mg index carries all six rungs
• Compounded GLP-1s (where still legally available): quoted per program; no published rate, and availability narrowed sharply in 2026
• Initial consultation: billed separately; telehealth intakes are generally cheaper than in-person or concierge clinics (clinics rarely publish rates)
• Baseline labs/bloodwork: billed separately and priced by panel breadth; follow-up panels are an additional charge
• Supplies (syringes, alcohol swabs, sharps container): a small recurring add-on, sometimes bundled into a telehealth subscription
• Insurance: rarely covers non-FDA-approved peptides; may cover FDA-approved GLP-1s for diabetes/obesity
• HSA/FSA: prescribed GLP-1s for a diagnosed condition are generally eligible

How much does peptide therapy cost per month?

There is no single "peptide therapy cost" because the category spans two very different worlds: FDA-approved drugs and non-approved compounded or research peptides.

For compounded research peptides — the category that includes BPC-157, TB-500, CJC-1295, ipamorelin, and sermorelin — there is no published price, and we do not publish a range. The ranges this guide used to carry were advertised figures scraped from clinic and telehealth listings, or repeated from third-party buying guides; nothing verified them, and the ones that were checked did not all survive the check, so they were withdrawn. Our price-per-mg index covers prescription pricing only, and its method note states what a first-party survey would have to show — sampling frame, collection date, number of sellers — before any range is published again. Until then the only figure that means anything for this category is the itemized quote you get in writing from the specific pharmacy or program.

For GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — the cost depends entirely on how you pay. Brand list prices are published by the manufacturers: $1,349.02 per package for Wegovy (NovoCare) and $1,027.51 for Ozempic (NovoCare). Manufacturer self-pay programs sit well below that: NovoCare charges $349/month for Wegovy at any dose and $399/month for the Wegovy HD 7.2 mg pen, with an introductory $199/month for the first two months at the 0.25 and 0.5 mg starting doses (NovoCare, retrieved September 2026). Eli Lilly publishes an equivalent self-pay ladder for the Zepbound single-patient-use KwikPen: a regular $299/month at 2.5 mg, $399/month at 5 mg, $499/month at 7.5 mg and $699/month each at 10 mg, 12.5 mg and 15 mg, with a purchase offer that holds the 7.5, 10, 12.5 and 15 mg doses at $449/month if each refill is bought within 45 days — at 2.5 and 5 mg the regular price is already lower, and the card that carries the offer expires December 31, 2026 (Lilly, retrieved September 30, 2026). Our price-per-mg index carries those six regular prices rather than the offer, and flags the 2.5 mg rung as a starting dose Lilly says is not approved as a maintenance dose. Lilly no longer publishes a reachable per-dose price for the single-dose vial, so the index carries no vial row. Introductory offers expire, so check the current tier for your own dose.

The economics matter. A peer-reviewed cost-effectiveness analysis estimated the net annual price of tirzepatide at roughly $6,236 and semaglutide at roughly $8,412, and concluded that neither was cost-effective at those prices versus lifestyle intervention — semaglutide carried an incremental cost-effectiveness ratio of $467,676 per quality-adjusted life-year and tirzepatide $197,023 per QALY, both far above the $100,000/QALY benchmark (Hwang et al., 2025, JAMA Health Forum) [1]. That study underlines why list prices are high even as cash-pay programs discount aggressively.

Consult your healthcare provider before starting any peptide protocol; price should never be the only factor in a medical decision.

Which peptides have a published price, and which do not?

The useful split is not by molecule but by whether anyone publishes a number you can check.

Because maintenance doses differ by molecule, two drugs at the same monthly price are not the same cost: Wegovy's 2.4 mg weekly is about 9.6 mg a month against Zepbound's 15 mg weekly at about 60 mg. Dollars per milligram is the only basis on which they compare, and our price-per-mg index computes it from the dose inputs printed beside each row rather than by hand.

A compounded BPC-157 vial and a brand GLP-1 are not priced in the same world, and the gap reflects the regulatory chasm between them rather than anything about relative value: one is a non-approved compounded substance with no published price, the other an FDA-approved drug that went through full clinical trials and whose list price the manufacturer publishes. For the underlying science behind a representative healing peptide, see our BPC-157 protocol guide — preclinical work has reported, for example, that the pentadecapeptide BPC 157 accelerated tendon-explant outgrowth and fibroblast migration in a rat/in-vitro model (Chang et al., 2011, J Appl Physiol) [2]. That is animal and cell-culture evidence, not proof of a human benefit, and it does not establish value for any price.

What hidden costs add to the price of peptide therapy?

The monthly vial price is rarely the whole bill. Budget for these add-ons:

• Initial consultation: billed separately. Telehealth intake visits sit at the lower end; in-person clinics and concierge practices charge more. Most clinics do not publish this rate, so ask for it up front.
• Baseline labs: priced by panel breadth. Some protocols require hormone, metabolic, or organ-function panels before starting.
• Follow-up labs: an additional charge per round, often at the 8–12 week mark.
• Injection supplies: syringes, alcohol swabs, bacteriostatic water (when applicable), and a sharps container — a small recurring cost.
• Shipping: built into many telehealth subscriptions; sometimes billed separately.
• Membership/subscription fees: many telehealth platforms bundle consult, prescription, medication, and monitoring into a flat monthly rate, which can be cheaper than paying à la carte. Compare the bundle against the itemised alternative before committing.

A protocol advertised at one monthly figure routinely costs more in the first month, once labs, supplies and any setup fee are added. We do not quote a first-month total, because no two programs bundle the same things. Always ask a provider for an itemized estimate. Consult your healthcare provider, and request a written breakdown of all fees before committing.

Does insurance cover peptide therapy?

Mostly, no — with one important exception.

Non-FDA-approved compounded peptides (BPC-157, TB-500, CJC-1295, and similar) are almost never covered by commercial insurance, because insurers generally do not reimburse non-approved or "wellness" compounds. You should expect to pay out of pocket.

FDA-approved GLP-1 drugs are different. When semaglutide or tirzepatide is prescribed for an on-label, diagnosed condition (type 2 diabetes, or obesity for the weight-loss formulations), some commercial and Medicare plans provide coverage, though coverage rules, prior-authorization requirements, and formulary placement vary widely and change frequently.

On the tax-advantaged side, prescribed GLP-1 medications used to treat a diagnosed medical condition are generally treated as qualified medical expenses eligible for HSA and FSA reimbursement, which lowers the effective cost by whatever your own marginal tax rate is — we do not quote a percentage, since that depends entirely on your bracket. Plan administrators may request a prescription and diagnosis documentation, and rules vary by plan; IRS Publication 502 sets out what counts as a qualified medical expense. Confirm specifics with your benefits administrator. Coverage is a financial question with medical implications — discuss both with your provider and your plan.

Why is GLP-1 peptide therapy so much more expensive?

The price gap is structural, not arbitrary.

GLP-1 drugs are branded, patent-protected, FDA-approved medications that completed large clinical-trial programs and demonstrated substantial weight loss in head-to-head and placebo-controlled studies. That development and approval pathway — plus patent exclusivity — supports a high list price. The cost-effectiveness research above (Hwang et al., 2025) [1] found these drugs deliver real long-term health gains (fewer modeled cases of diabetes and cardiovascular disease) but cost more per QALY than standard value thresholds accept, which is precisely why list prices are high and why manufacturers run discounted cash-pay programs to compete on price.

Compounded research peptides, by contrast, skip that approval pathway entirely. They are prepared by compounding pharmacies (or sold as "research-use-only" chemicals), have not completed human efficacy trials, and are priced like specialty compounds rather than patented drugs. Lower price here reflects lower regulatory burden and unproven human efficacy — not a better deal in clinical terms. Compare the two GLP-1 leaders in our semaglutide vs. tirzepatide breakdown.

How will the FDA's 2026 changes affect peptide therapy cost?

2026 is a pivotal regulatory year, and it could change both availability and price for several popular peptides.

On April 16, 2026, the FDA published a Federal Register notice scheduling a Pharmacy Compounding Advisory Committee (PCAC) meeting for July 23–24, 2026 to evaluate whether several peptide bulk drug substances should be added to the Section 503A Bulk Drug Substances List — the list that governs which substances state-licensed pharmacies may compound for individual patients (FDA, Federal Register notice 2026-07361; Docket FDA-2025-N-6895) [3]. The panel said yes to six and no to emideltide (DSIP); the FDA still has to write the rule — see the full picture. On July 23, the committee discussed BPC-157, KPV, TB-500, and MOTS-C; on July 24, Emideltide (DSIP), Semax, and Epitalon (FDA PCAC meeting announcement) [4].

Two points matter for cost and legality:

1. Removal from the restricted "Category 2" list is not the same as authorization to compound. Even if PCAC recommends adding a peptide to the 503A list, the FDA must still complete formal notice-and-comment rulemaking — a process that can take more than a year — before licensed pharmacies may legally compound it [3][4].
2. 503A and 503B are different pathways. Under Section 503A, compounding requires a valid prescription for an individual patient and is overseen primarily by states; Section 503B outsourcing facilities register with and are inspected by the FDA and may produce "office stock" (FDA, Bulk Drug Substances guidance) [5]. A peptide could be addressed on one list and not the other.

The practical takeaway: if a peptide gains a legitimate 503A compounding pathway, supply may shift from gray-market "research" vendors to licensed pharmacies, which could change pricing, quality assurance, and where you can legally obtain it. If it does not, current availability may tighten. Learn more in our overview of whether BPC-157 is legal. Legal status varies by jurisdiction; consult a lawyer for binding advice, and a licensed provider for medical guidance.

For NYC-specific access, our guide to peptide clinics in Manhattan covers how local clinics and telehealth providers structure their charges.

Where this fits: it is one entry in our Sourcing library, and our Healing hub collects every guide aimed at the same outcome. If you are weighing the two tissue-repair peptides against each other, our BPC-157 vs TB-500 comparison puts them side by side. For the two leading GLP-1 options head to head, see tirzepatide vs semaglutide.

Frequently asked questions

Q: How much does peptide therapy cost per month on average? A: For compounded research peptides like BPC-157 or TB-500 there is no average to quote: nobody publishes a rate, every pharmacy and telehealth program sets its own, and the ranges this guide used to give were advertised figures we never verified, so they were withdrawn. For GLP-1 weight-loss drugs the published figures are $1,349.02 per package for Wegovy and $1,027.51 per month for Ozempic at list price, and $349/month for Wegovy through Novo Nordisk's self-pay program (NovoCare, retrieved September 2026). All of those exclude consultation and lab fees. Get an itemized quote in writing, and discuss whether any peptide is appropriate for you with a licensed healthcare provider.

Q: Why is compounded BPC-157 so much cheaper than a GLP-1 drug? A: BPC-157 is a non-FDA-approved compounded peptide that has not completed human efficacy trials, so it is priced like a specialty compound. GLP-1 drugs like Wegovy and Zepbound are patent-protected, FDA-approved medications that completed large clinical-trial programs, which supports a much higher list price. Lower cost does not mean better value clinically — it reflects a lower regulatory bar and unproven human efficacy. Consult your healthcare provider before considering either.

Q: Does insurance cover peptide therapy? A: Non-approved compounded peptides such as BPC-157, TB-500, and CJC-1295 are almost never covered by commercial insurance, so you should expect to pay out of pocket. FDA-approved GLP-1 drugs may be covered when prescribed for an on-label diagnosed condition like type 2 diabetes or obesity, but coverage rules and prior-authorization requirements vary widely. Check directly with your plan and your provider.

Q: Can I use an HSA or FSA to pay for peptide therapy? A: Prescribed GLP-1 medications used to treat a diagnosed condition like obesity or type 2 diabetes are generally eligible HSA/FSA expenses, which reduces the effective cost by whatever your own marginal tax rate is — we do not quote a percentage, because that depends entirely on your bracket. Documentation — a prescription, itemized receipt, and sometimes diagnosis records — may be required, and rules vary by plan and administrator. Eligibility for non-approved "wellness" peptides is far less certain. Confirm with your benefits administrator before purchasing.

Q: What hidden costs should I budget for beyond the vial price? A: Beyond the monthly medication, plan for an initial consultation, baseline labs, follow-up labs, injection supplies, and possibly shipping or membership fees — all billed separately and most of them not published in advance. A protocol advertised at one monthly figure routinely costs more in the first month once setup and labs are included. Ask any provider for a written, itemized estimate before you commit.

Q: Will the FDA's 2026 PCAC review change peptide prices? A: It could. The FDA's Pharmacy Compounding Advisory Committee reviewed BPC-157, TB-500, KPV, MOTS-C, DSIP, Semax, and Epitalon on July 23–24, 2026, and voted on whether they belong on the 503A compounding list. If a peptide gains a legitimate compounding pathway after formal rulemaking, supply could move from gray-market vendors to licensed pharmacies, potentially changing price and quality assurance. If not, availability may tighten. The outcome is not final and rulemaking can take over a year.

Q: Is cheaper peptide therapy safe? A: Price is not a safety indicator. A low-cost "research-use-only" peptide may carry no quality assurance, purity testing, or sterility guarantee, whereas a higher-priced FDA-approved drug or licensed-pharmacy compound is held to defined standards. Sourcing, purity (ideally with a certificate of analysis), and provider oversight matter far more than headline price. Consult your healthcare provider before starting any peptide protocol, regardless of cost.

References

1. Hwang JH, Laiteerapong N, Huang ES, Kim DD. Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults. JAMA Health Forum. 2025. PMID: 40085108. DOI: 10.1001/jamahealthforum.2024.5586.
2. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-780. PMID: 21030672. DOI: 10.1152/japplphysiol.00945.2010.
3. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments — Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List. Federal Register. April 16, 2026. Docket No. FDA-2025-N-6895. Federal Register notice 2026-07361.
4. U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA Advisory Committee Calendar.
5. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. FDA Human Drug Compounding.